L-Phenylalanine Veg

Phase 3Small molecule

WWeill Medical College of Cornell University

L-Phenylalanine Veg is one of 2 small molecule programs targeting Gut Microbiome. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Gut MicrobiomeRecruiting

Gut MicrobiomePhase 3

Recruiting

Competition

Competitive Landscape

2 competitors in Gut Microbiome

#DrugCompanyPhaseTrials

L-Ornithine L-Aspartate

IInstitute of Liver and Biliary Sciences, India

Phase 3

1 2

L-Phenylalanine Veg

WWeill Medical College of Cornell University

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

ApprovedRecruiting

Gut Microbiome

NCT06433310

Clinical

Trials by Indication[1]

Gut Microbiome1 trial

Understanding the Efficacy of Dietary Supplement on Fungal Mycobiota in Healthy Volunteers: A Pilot Study

Recruiting·WWeill Medical College of Cornell University·Approved·NCT06433310·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for L-Phenylalanine Veg. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — L-Phenylalanine Veg compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for L-Phenylalanine Veg. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Weill Medical College of Cornell University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: WWeill Medical College of Cornell University

L-Phenylalanine Veg

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Gut Microbiome1 trial

References

Drug Info

Quick Facts

Related News